Last reviewed · How we verify
Coversin
Coversin is a Small molecule drug developed by AKARI Therapeutics. It is currently in Phase 2 development. Also known as: rVA576, rEV576.
Coversin is a leukotriene B4 receptor inhibitor, classified as an inhibitor drug. It is being studied for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a Phase III clinical trial.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Coversin |
|---|---|
| Also known as | rVA576, rEV576 |
| Sponsor | AKARI Therapeutics |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms (PHASE2)
- rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study (PHASE3)
- Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 (PHASE3)
- Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coversin CI brief — competitive landscape report
- Coversin updates RSS · CI watch RSS
- AKARI Therapeutics portfolio CI
Frequently asked questions about Coversin
What is Coversin?
Who makes Coversin?
Is Coversin also known as anything else?
What development phase is Coversin in?
Related
- Manufacturer: AKARI Therapeutics — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: rVA576, rEV576
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing